TrICI: Trauma Induced Coagulopathy and Inflammation

Sponsor
University of Pennsylvania (Other)
Overall Status
Completed
CT.gov ID
NCT03128658
Collaborator
Princeton University (Other)
300
1
46.1
6.5

Study Details

Study Description

Brief Summary

While a number of factors are known to be associated with the development of trauma induced coagulopathy (TIC), inflammation, and multi-organ failure, we currently cannot predict which patients are at risk for developing these life threatening conditions with any certainty. In this prospective observational study, we will investigate the many factors that contribute to the development of trauma induced coagulopathy, post injury inflammation and the development of organ dysfunction in order to develop a multi scale computational algorithm of clinical prediction. Using a convenience sample technique, demographic data, physiologic data, blood samples and clinical variables will be collected over 5 days following traumatic injury. A computational model will be used to predict the development of TIC and multi-organ failure.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Thromboelastography
  • Diagnostic Test: Computational model

Detailed Description

A prospective, observational, convenience sample of trauma patients 18 years old or older who present to the trauma bay as a trauma alert will be included after evaluation by the on-call trauma surgeon and research assistant. Minimally injured patients will be compared to those with a systolic blood pressure of 90 mmHg or less, the need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15. Demographic data including past medical/medication history as well as clinical data including continuous vital signs will be recorded. If eligibility criteria are met, the research blood samples will be drawn at the same time as routine clinical samples. Blood samples (approximately 15 ml) will be taken on admission, 3hr, 6hrs, 12hrs, 24 hrs, 48 hrs, and 5 days post admission. Vital signs, number of blood transfusions, volume of crystalloid, administration of medications, and the values of routine laboratories will be monitored continuously for 24 hours, and then cumulatively for up to 5 days. After the last blood draw, we will be following the patient's outcome for up to 30 days. If patients are discharged or die prior to completing the 5 days of blood samples, additional samples and/or clinic appointments for the purpose of research will not be obtained. A computational algorithm will be used to predict the development of trauma induced coagulopathy, inflammation and multi-organ failure.

Study Design

Study Type:
Observational
Actual Enrollment :
300 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Trauma Induced Coagulopathy and Inflammation
Actual Study Start Date :
Feb 27, 2017
Actual Primary Completion Date :
Dec 31, 2020
Actual Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Trauma patients

Trauma patients with a systolic blood pressure of 90 mmHg or less, in need for blood product transfusion within 1 hour of admission, and/or an ISS (injury severity score) of greater than or equal to 15.

Diagnostic Test: Thromboelastography
Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)

Diagnostic Test: Computational model
The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.

Outcome Measures

Primary Outcome Measures

  1. Change in Thromboelastography parameters T0 -T3 [Between time of admission (T0) and 3 hours (T3)]

    Variables: Reaction time (R value), the K value, the angle and the maximum amplitude (MA)

  2. Change in Thromboelastography parameters T3 -T6 [Between 3 hours (T3) and 6 hours (T6)]

    Variables: Reaction time (R value), the K value, the angle and the maximum amplitude (MA)

  3. Change in Thromboelastography parameters T6 -T12 [Between 6 hours (T6) and 12 hours (T12)]

    Variables: Reaction time (R value), the K value, the angle and the maximum amplitude (MA)

  4. Change in Thromboelastography parameters T12 - T24 [Between 12 hours (T12) and 24 hours (T24)]

    Variables: Reaction time (R value), the K value, the angle and the maximum amplitude (MA)

  5. Change in Thromboelastography parameters T24 - T48 [Between 24 hours (T24) and 48 hours (T48)]

    Variables: Reaction time (R value), the K value, the angle and the maximum amplitude (MA)

  6. Change in Thromboelastography parameters T48 - T120 [Between 48 hours (T48) and 120 hours (T120)]

    Variables: Reaction time (R value), the K value, the angle and the maximum amplitude (MA)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Injured patients presenting to the trauma bay with a trauma alert activation (highest level of activation)

  • Age 18 years old or more

Exclusion Criteria:
  • Transfer duration to trauma service exceeding 6 hours.

  • Known pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Penn Presbyterian Medical Center Philadelphia Pennsylvania United States 19104

Sponsors and Collaborators

  • University of Pennsylvania
  • Princeton University

Investigators

None specified.

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT03128658
Other Study ID Numbers:
  • 826515
First Posted:
Apr 25, 2017
Last Update Posted:
Mar 9, 2021
Last Verified:
Mar 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Pennsylvania
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 9, 2021